The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Evaluate predicts sales could approach $8bn if approved.
Drug tops list compiled by Evaluate Pharma
Alecensa part of Roche’s goal of becoming dominant player in NSCLC
Body unconvinced by clinical data for Venclyxto .
Leukaemia drug latest to move out of Cancer Drugs Fund
Approval by May could put Keytruda in pole position